

Supporting smart decisions and care equity along the care continuum



No matter where your patient is with their cancer, Exact Sciences can help provide earlier detection and smarter answers.

Understanding a patient's risk of developing inherited forms of cancer, why cancer may be common in their family, and their screening options can help physicians create personalized health care plans. Exact Sciences has joined forces with PreventionGenetics to add Riskguard™ —a 32-gene Next-Generation Sequencing hereditary multi-cancer panel—to our growing portfolio of oncology tests throughout the care continuum.

For patients diagnosed with early-stage breast or colon cancer, Exact Sciences' precision oncology portfolio of tests can aid clinicians in treatment decisions. Each patient is unique; that means every tumor is different. With the genomic-based insights of Oncotype DX Breast Recurrence Score® and Oncotype DX Colon Recurrence Score® tests, clinicians can make informed decisions with actionable data customized to each patient's situation. The Oncotype DX® tests deliver clinically relevant genomic intelligence specific to the individual biology of a patient's tumor—equipping physicians with the individualized insights they need to make a personalized treatment decision for the patient.

Exact Sciences' portfolio of tests can also aid in therapy selection for patients with advanced, metastatic, refractory, relapsed, or recurrent solid tumors. The OncoExTra™ test delivers rapid and comprehensive tumor profiling which aids in therapy selection. It is an ultra-comprehensive genomic profiling assay that sequences both the whole exome and whole transcriptome (WES/WTS). OncoExTra™ reports clinically actionable mutations, copy number alterations, transcript variants/fusions through DNA and RNA analyses. Findings are mapped to a knowledge base of available therapies as well as relevant clinical trial options - equipping physicians with the most actionable insights for therapy selection.

Exact Sciences aims to be a partner for patients, providers, and health systems by creating solutions to unmet needs across the cancer care continuum, from screening to therapy selection. **Exact Sciences is committed to continue changing the landscape of cancer care through innovation and collaborating with health systems** to help people get the answers they need to make more informed decisions across the cancer continuum including research in the space of molecular residual disease and others.